Search results

This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs

This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance

This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages

This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented

This methods guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it

This process guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it

This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs

This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs

This guide outlines the main elements of the interim NICE clinical guideline surveillance process and methodology, which was agreed by the NICE Board in July 2013